Scarica l'app Stockscreener
213.47
0.85%
-1.84
Dopo l'orario di chiusura:
214.08
0.61
+0.29%
Natera Inc Borsa (NTRA) Ultime notizie
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC - Yahoo Finance
Natera Pushes MRD And Panorama Into Treatment Guiding Roles - Yahoo Finance
Billionaire Stanley Druckenmiller Likes This Cancer Stock - Insider Monkey
How Investors May Respond To Natera (NTRA) Expanding Signatera MRD Reach Amid Insider Share Sale - simplywall.st
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
This Insider Has Just Sold Shares In Natera - Moomoo
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Net income of Natera, Inc. – XETR:45E - TradingView
Assessing Natera (NTRA) Valuation After Strong Multi Year Returns And Recent Share Price Cooling - simplywall.st
5 Healthcare Stocks That the AI Crowd Is Overlooking - Barron's
Natera, Inc. Balance Sheet – XETR:45E - TradingView
Goldman Sachs Initiates Natera(NTRA.US) With Hold Rating, Announces Target Price $245 - Moomoo
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Insider Sell Alert: Steven Chapman Sells 41,124 Shares of Natera Inc (NTRA) - GuruFocus
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com South Africa
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$9.09 Million in Common Stock - Moomoo
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - Stock Titan
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Expands Board, Appoints Thomas Lynch as Director - TipRanks
Natera (NTRA) appoints independent director Thomas Lynch and expands board - Stock Titan
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com South Africa
Natera CytoDyn Signatera Pact Highlights Data Assets And Rich Valuation - simplywall.st
Natera partners with CytoDyn on cancer treatment research By Investing.com - Investing.com South Africa
Steven L. Chapman reports common‑share sales (NASDAQ: NTRA) - Stock Titan
CytoDyn (CYDY) Teams Up with Natera for Cancer Research Collaboration - GuruFocus
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer - CytoDyn Inc.
Natera Inc stock (US6323071042): insider sales and new oncology board appointments in focus - AD HOC NEWS
Natera expands Austin operations with new sequencing facility - MSN
Natera, CytoDyn Partner in Colorectal Cancer Study - Contract Pharma
Natera partners with CytoDyn on cancer treatment research - Investing.com
DNA blood test to track tumors in new colon cancer drug trial - Stock Titan
Natera adds two oncology experts to board of directors - Investing.com UK
Insider Sell Alert: Solomon Moshkevich Sells 3,000 Shares of Nat - GuruFocus
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors - BioSpace
Natera president sells $655,294 of common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under 10b5-1 plan - Stock Titan
Natera president sells $655,294 of common stock By Investing.com - Investing.com Canada
Natera(NTRA.US) Director Sells US$17.18 Million in Common Stock - Moomoo
Director Roelof Botha-linked vehicles sell 78K Natera (NTRA) shares - Stock Titan
Natera Adds Oncology Veterans Thomas Lynch and Eric Rubin to Board - citybiz
IVF Patients Say Natera Profited Off Ineffective Embryo Tests - Law360
Natera adds two oncology experts to board of directors By Investing.com - Investing.com South Africa
0.13%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):